Drug Eluting Stent Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Drug Eluting Stent Market is segmented By Coating (Polymer Based Coating (Biodegradable, Non-biodegradable), Polymer Free Coating), By Application and Geography.

Market Drug Eluting Stent Market

Drug Eluting Stent Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The drug eluting stent market is expected to register a CAGR of 5.3% during the forecast period. The drug eluting stent is a semi-rigid, tube-like device which is made of metal and coated with medication that is slowly released or eluted which helps to block cell proliferation. The introduction of the drug eluting stent (DES) has further pushed the medical technology to a new standard of care.

The drug eluting stents are of different types, first, second and third-generation DESs (drug eluting stents). First-generation drug eluting stents significantly decreased the risk of in-stent restenosis observed with bare-metal stent (BMS), their use was complicated by late and very late stent thrombosis. Second generation drug eluting stents have decreased risk and the rate of one-year stent thrombosis. There are three main components in drug eluting stent, the metal stent structure generally made up of surgical stainless steel or a cobalt-chromium alloy, metal stent coating contains the drug and delivers (elutes) it to the arterial wall over a period of time and the drug itself which suppresses the formation of excess tissue. Rapid technological advancements in stent designs and delivery systems have been reducing the cases of restenosis, even for the most complex lesions. The most recent generation of drug-eluting stents, are associated with a significant reduction in the risk of early and late thrombosis.

According to the American Heart Association, coronary artery diseases account for the highest number of deaths in the United States, affecting more than 13 million people. Every year, nearly 610,000 people die of heart disease in the United States, 1 in every 4 deaths. In addition, according to the World Health Organization (WHO), in the year 2016, worldwide about 31% of deaths are due to cardiovascular diseases (CVDs).

Rise in the geriatric population, increasing prevalence of cardiovascular diseases and growing demand for minimally invasive surgeries are the key driving factors in drug eluting stent market.

Scope of the Report

The drug eluting stent is a semi-rigid, tube-like device which is made of metal and coated with medication that is slowly released or eluted which helps to block cell proliferation. Drug Eluting Stent Market is segmented By Coating, By Application and Geography.

By Coating
Polymer Based Coating
Biodegradable
Non-biodegradable
Polymer Free Coating
By Application
Coronary Artery Disease
Peripheral Artery Disease
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Polymer Free Coating Stents Segment is Expected to Hold a Major Market Share in the Drug Eluting Stent Market

  • Polymer free coating stents comprise microporous stents and inorganic coatings that can be drug-loaded. Several drugs such as tacrolimus, paclitaxel, sirolimus, and probucol have been used in the design of carrier-free stents.
  • According to the World Health Organization (WHO), globally cardiovascular diseases (CVDs) are the number 1 cause of death, an estimated 17.9 million each year suffer from cardiovascular diseases. Four out of 5 cardiovascular deaths are due to strokes and heart attacks, and one-third of deaths occur prematurely in people under 70 years of age.
  • Polymer free coating stents segment holds a significant market share in the drug eluting stent market and is anticipated to show a similar trend over the forecast period due to higher drug loading capacity of nanoporous surfaces and quicker drug eluting rate.
  • Rise in the geriatric population, increasing prevalence of cardiovascular diseases and growing demand for minimally invasive surgeries are the key driving factors in the polymer-free coating stents segment.
Drug Eluting Stent Key trend 1

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the drug eluting stent market due to favorable reimbursement policies coupled with a high incidence rate of artery diseases in this region. According to the Centers for Disease Control and Prevention (CDC), about 365,914 people in the United States died due to coronary heart disease in the year 2017. Approximately, 18.2 million individuals above 20 years of age have coronary artery disease which accounts for about 6.7% of adult population. In addition, about 2 in 10 deaths from coronary artery disease happen in adults less than 65 years old. Moreover, technological advancements in the drug eluting stents and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Drug Eluting Stent Market 2

Competitive Landscape

The Drug Eluting Stent Market is consolidated competitive and consists of few major players.  Some of the companies which are currently dominating the market are Boston Scientific Corporation, Terumo Corporation, Abbott Laboratories, Medtronic Plc, Biotronik SE & Co. KG, Biosensors International Group, Ltd, MicroPort Scientific Corporation, Cook Medical, Shandong JW Medical Systems and Stentys SA.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Geriatric Population and Increasing Prevalence of Cardiovascular Diseases

      2. 4.2.2 Growing Demand for Minimally Invasive Surgeries

    3. 4.3 Market Restraints

      1. 4.3.1 Strict Regulatory Approval Process of Products

      2. 4.3.2 Adverse Effects associated with the Drug Eluting Stents coupled with Product Recalls

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Coating

      1. 5.1.1 Polymer Based Coating

        1. 5.1.1.1 Biodegradable

        2. 5.1.1.2 Non-biodegradable

      2. 5.1.2 Polymer Free Coating

    2. 5.2 By Application

      1. 5.2.1 Coronary Artery Disease

      2. 5.2.2 Peripheral Artery Disease

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Boston Scientific Corporation

      2. 6.1.2 Terumo Corporation

      3. 6.1.3 Abbott Laboratories

      4. 6.1.4 Medtronic Plc

      5. 6.1.5 Biotronik SE & Co. KG

      6. 6.1.6 Biosensors International Group, Ltd

      7. 6.1.7 MicroPort Scientific Corporation

      8. 6.1.8 Cook Medical

      9. 6.1.9 Shandong JW Medical Systems

      10. 6.1.10 Stentys SA

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Drug Eluting Stent Market market is studied from 2018 - 2026.

The Drug Eluting Stent Market is growing at a CAGR of 5.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Boston Scientific Corporation, Terumo Corporation, Abbott Laboratories, Medtronic Plc, Biotronik SE & Co. KG are the major companies operating in Drug Eluting Stent Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!